Our study demonstrated that the use of DPP-4 inhibitors in T2DM patients with chronic HBV infection can significantly decrease the risk of HCC (aHRs: 0.53, 95% CIs: 0.44–0.65). The gene discussed is DPP4; the disease is hepatocellular carcinoma.